Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitors”

2,466 pharma patents match "inhibitors" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,466
Index total 30,257
Page 14 / 103

Quick answer

This filtered view shows 2,466 pharmaceutical patents matching "inhibitors" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,466 results for “inhibitors” · 30,257 patents in full index Clear search

  1. US 11672791

    Tyrosine kinase inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Jun 13, 2023 · Expires Jun 8, 2043

    granted
  2. US 11672793

    Compositions of CXCR4 inhibitors and methods of preparation and use

    X4 Pharmaceuticals, Inc. · Granted Jun 13, 2023 · Expires Jun 8, 2043

    granted
  3. US 11672774

    Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Jun 13, 2023 · Expires Jun 8, 2043

    granted
  4. US 11666606

    Methods of treating joint disease, disorders and conditions with tissue inhibitors of matrix metalloproteinases

    Prime Merger Sub, LLC · Granted Jun 6, 2023 · Expires Jun 1, 2043

    granted
  5. US 11667637

    Fused imidazo-piperidine JAK inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Jun 6, 2023 · Expires Jun 1, 2043

    granted
  6. US 11667643

    RIP1K inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Jun 6, 2023 · Expires Jun 1, 2043

    granted
  7. US 11666645

    CD200 inhibitors and methods of use thereof

    Regents of the University of Minnesota · Granted Jun 6, 2023 · Expires Jun 1, 2043

    granted
  8. US 11661426

    Imidazole-containing inhibitors of ALK2 kinase

    BioCryst Pharmaceuticals, Inc. · Granted May 30, 2023 · Expires May 25, 2043

    granted
  9. US 11661401

    2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors

    Revolution Medicines, Inc. · Granted May 30, 2023 · Expires May 25, 2043

    granted
  10. US 11654147

    ALK2 inhibitors and methods for inhibiting BMP signaling

    The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted May 23, 2023 · Expires May 18, 2043

    granted
  11. US 11654157

    Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation

    Shuttle Pharmaceuticals, Inc. · Granted May 23, 2023 · Expires May 18, 2043

    granted
  12. US 11654142

    Methods for the administration of certain VMAT2 inhibitors

    Neurocrine Biosciences, Inc. · Granted May 23, 2023 · Expires May 18, 2043

    granted
  13. US 11649251

    Substituted inhibitors of menin-MLL and methods of use

    Kura Oncology, Inc. · Granted May 16, 2023 · Expires May 11, 2043

    granted
  14. US 11643388

    Inhibitors of alpha 2 beta 1 integrin and methods of use thereof

    The Regents of the University of California · Granted May 9, 2023 · Expires May 4, 2043

    granted
  15. US 11639355

    Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors

    Medshine Discovery Inc. · Granted May 2, 2023 · Expires Apr 27, 2043

    granted
  16. US 11639364

    Potent sialyltransferase inhibitors

    Stichting Radboud universitair medisch centrum · Granted May 2, 2023 · Expires Apr 27, 2043

    granted
  17. US 11634413

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted
  18. US 11629145

    SHP2 phosphatase inhibitors and methods of use thereof

    Relay Therapeutics, Inc. · Granted Apr 18, 2023 · Expires Apr 13, 2043

    granted
  19. US 11622970

    BCL-2 inhibitors and their use as pharmaceuticals

    Prelude Therapeutics, Incorporated · Granted Apr 11, 2023 · Expires Apr 6, 2043

    granted
  20. US 11617742

    Methods of treating keratin hyperproliferation disorders using mTOR inhibitors

    PALVELLA THERAPEUTICS, INC. · Granted Apr 4, 2023 · Expires Mar 30, 2043

    granted
  21. US 11618746

    Inhibitors of APOL1 and methods of using same

    Vertex Pharmaceuticals Incorporated · Granted Apr 4, 2023 · Expires Mar 30, 2043

    granted
  22. US 11618731

    Prodrugs of kallikrein inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Apr 4, 2023 · Expires Mar 30, 2043

    granted
  23. US 11613527

    Enzyme inhibitors

    KalVista Pharmaceuticals Limited · Granted Mar 28, 2023 · Expires Mar 23, 2043

    granted
  24. US 11613528

    Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Mar 28, 2023 · Expires Mar 23, 2043

    granted